A pair of oncology program presentations
LEXINGTON, Mass.—Biotechnology company Curis Inc. recently announced that its collaborator Aurigene shared preclinical data from two programs AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. Those programs included CA-170, a first-in-class oral, small-molecule immune checkpoint antagonist targeting programmed death ligand-1 (PD-L1) and V-domain Ig suppressor of T cell activation (VISTA), and the interleukin-1 receptor associated kinase 4 (IRAK4) inhibitor program. Curis exercised options to license the programs under a collaboration agreement with Aurigene struck earlier this year.
“The collective in-vitro and animal model data are very compelling and strongly support testing of CA-170 in human clinical trials in multiple cancers,” said Dr. Ali Fattaey, Curis’ president and CEO. “We are working with Aurigene to complete the IND enabling studies for CA-170 and initiate clinical studies in the first half of 2016.”